These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


284 related items for PubMed ID: 27840158

  • 1. Polyethylenimine-functionalized carbon nanotubes tagged with AS1411 aptamer for combination gene and drug delivery into human gastric cancer cells.
    Taghavi S, Nia AH, Abnous K, Ramezani M.
    Int J Pharm; 2017 Jan 10; 516(1-2):301-312. PubMed ID: 27840158
    [Abstract] [Full Text] [Related]

  • 2. Prostate cancer cell death produced by the co-delivery of Bcl-xL shRNA and doxorubicin using an aptamer-conjugated polyplex.
    Kim E, Jung Y, Choi H, Yang J, Suh JS, Huh YM, Kim K, Haam S.
    Biomaterials; 2010 Jun 10; 31(16):4592-9. PubMed ID: 20206379
    [Abstract] [Full Text] [Related]

  • 3. Preparation and evaluation of polyethylenimine-functionalized carbon nanotubes tagged with 5TR1 aptamer for targeted delivery of Bcl-xL shRNA into breast cancer cells.
    Taghavi S, HashemNia A, Mosaffa F, Askarian S, Abnous K, Ramezani M.
    Colloids Surf B Biointerfaces; 2016 Apr 01; 140():28-39. PubMed ID: 26731195
    [Abstract] [Full Text] [Related]

  • 4. Synthesis of Aptamer-PEI-g-PEG Modified Gold Nanoparticles Loaded with Doxorubicin for Targeted Drug Delivery.
    Nie L, Sun S, Sun M, Zhou Q, Zhang Z, Zheng L, Wang L.
    J Vis Exp; 2020 Jun 23; (160):. PubMed ID: 32658190
    [Abstract] [Full Text] [Related]

  • 5. Study and evaluation of nucleolin-targeted delivery of magnetic PLGA-PEG nanospheres loaded with doxorubicin to C6 glioma cells compared with low nucleolin-expressing L929 cells.
    Mosafer J, Teymouri M, Abnous K, Tafaghodi M, Ramezani M.
    Mater Sci Eng C Mater Biol Appl; 2017 Mar 01; 72():123-133. PubMed ID: 28024568
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. FOXM1 Aptamer-Polyethylenimine Nanoplatform Coated With Hyaluronic Acid And AS1411 Aptamer For Dual-Targeted Delivery of Doxorubicin And Synergistic Treatment of Tumor Cells.
    Khademi Z, Yazdi KS, Ramezani M, Alibolandi M, Rezvani SA, Abnous K, Taghdisi SM.
    J Pharm Sci; 2024 Aug 01; 113(8):2198-2207. PubMed ID: 38432623
    [Abstract] [Full Text] [Related]

  • 8. Cell Surface Nucleolin as a Promising Receptor for Effective AS1411 Aptamer-Mediated Targeted Drug Delivery into Cancer Cells.
    Mosafer J, Mokhtarzadeh A.
    Curr Drug Deliv; 2018 Aug 01; 15(9):1323-1329. PubMed ID: 30039760
    [Abstract] [Full Text] [Related]

  • 9. Targeted delivery of doxorubicin to cancer cells by a cruciform DNA nanostructure composed of AS1411 and FOXM1 aptamers.
    Abnous K, Danesh NM, Ramezani M, Charbgoo F, Bahreyni A, Taghdisi SM.
    Expert Opin Drug Deliv; 2018 Nov 01; 15(11):1045-1052. PubMed ID: 30269603
    [Abstract] [Full Text] [Related]

  • 10. pH-responsive complexes using prefunctionalized polymers for synchronous delivery of doxorubicin and siRNA to cancer cells.
    Dong DW, Xiang B, Gao W, Yang ZZ, Li JQ, Qi XR.
    Biomaterials; 2013 Jul 01; 34(20):4849-59. PubMed ID: 23541420
    [Abstract] [Full Text] [Related]

  • 11. Enhanced Lysosomal Escape of pH-Responsive Polyethylenimine-Betaine Functionalized Carbon Nanotube for the Codelivery of Survivin Small Interfering RNA and Doxorubicin.
    Cao Y, Huang HY, Chen LQ, Du HH, Cui JH, Zhang LW, Lee BJ, Cao QR.
    ACS Appl Mater Interfaces; 2019 Mar 13; 11(10):9763-9776. PubMed ID: 30776886
    [Abstract] [Full Text] [Related]

  • 12. Targeted delivery of melittin to cancer cells by AS1411 anti-nucleolin aptamer.
    Rajabnejad SH, Mokhtarzadeh A, Abnous K, Taghdisi SM, Ramezani M, Razavi BM.
    Drug Dev Ind Pharm; 2018 Jun 13; 44(6):982-987. PubMed ID: 29325460
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. A Synthetic Aptamer-Drug Adduct for Targeted Liver Cancer Therapy.
    Trinh TL, Zhu G, Xiao X, Puszyk W, Sefah K, Wu Q, Tan W, Liu C.
    PLoS One; 2015 Jun 13; 10(11):e0136673. PubMed ID: 26523833
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 15.